BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Investigation of the combined effects of BCR/ABL inhibition with Imatinib and the multi-HDAC inhibitor panobinostat was performed in K562 cells The combination of panobinostat with imatinib was reported to have synergistic antileukemic effects and increased treatment effectiveness in K562 cells generated from CML patients (Zehtabcheh et al., 2021).